The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy

The Flt3L/Flt3 Axis in Dendritic Cell Biology and Cancer Immunotherapy

Dendritic cells (DCs) prime anti-tumor T cell responses in tumor-draining lymph nodes and can restimulate T effector responses in the tumor site. Thus, in addition to unleashing T cell effector activity, current immunotherapies should be directed to boost DC function. Herein, we review the potential...

Full description

Bibliographic Details
Main Authors:	Francisco J. Cueto, David Sancho
Format:	Article
Language:	English
Published:	MDPI AG 2021-03-01
Series:	Cancers
Subjects:	Flt3 Flt3L dendritic cells cancer immunotherapy
Online Access:	https://www.mdpi.com/2072-6694/13/7/1525

Similar Items

Role of Biomarkers in FLT3 AML
by: Nitika, et al.
Published: (2022-02-01)

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors
by: Tristan E. Knight, et al.
Published: (2022-07-01)

FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
by: Vanessa E. Kennedy, et al.
Published: (2020-12-01)

Discovery of 5-methyl-N-(2-arylquinazolin-7-yl)isoxazole-4-carboxamide analogues as highly selective FLT3 inhibitors
by: Daseul Im, et al.
Published: (2020-01-01)

FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and the impact of FLT3-ITD mutations on the survival of patients with a normal karyotype
by: Irina Stepanovna Martynkevich, et al.
Published: (2010-12-01)

Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
by: Juanjuan Zhao, et al.
Published: (2019-09-01)

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
by: Tecik M, et al.
Published: (2022-11-01)

Early-life hyperoxia-induced Flt3L drives neonatal lung dendritic cell expansion and proinflammatory responses
by: Tracy X. Cui, et al.
Published: (2023-02-01)

Regulatory Dendritic Cells Induced by Bendamustine Are Associated With Enhanced Flt3 Expression and Alloreactive T-Cell Death
by: Megan S. Molina, et al.
Published: (2021-06-01)

Comparison of high-resolution melting analysis with direct sequencing for detection of FLT3-TKD, FLT3-ITD and WT1 mutations in acute myeloid leukemia
by: Aida Mahmoudi, et al.
Published: (2021-01-01)

First Report of Sorafenib in Patients With Acute Myeloid Leukemia Harboring Non-Canonical FLT3 Mutations
by: Naval Daver, et al.
Published: (2020-08-01)

Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
by: Ying Wang, et al.
Published: (2018-05-01)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
by: Dan Xu, et al.
Published: (2022-07-01)

Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models
by: Emile J. Clappaert, et al.
Published: (2023-08-01)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2020-10-01)

CPX-351 in FLT3-mutated acute myeloid leukemia
by: Claire Andrews, et al.
Published: (2023-11-01)

FLT3/ITD associated with an immature immunophenotype in PML-RARα leukemia
by: Mariko Takenokuchi, et al.
Published: (2012-10-01)

Regression of leukemia cutis with gilteritinib in a case of FLT3-positive acute myeloid leukemia
by: Andrea Duminuco, et al.
Published: (2022-09-01)

Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
by: Sebastian Scholl, et al.
Published: (2020-11-01)

Introduction of Human Flt3-L and GM-CSF into Humanized Mice Enhances the Reconstitution and Maturation of Myeloid Dendritic Cells and the Development of Foxp3+CD4+ T Cells
by: Ryutaro Iwabuchi, et al.
Published: (2018-05-01)

FLT3-ITD Incidence and FLT-D835 Mutations in Acute Myeloid Leukemia Patients with Normal Karyotype in Morocco: A Preliminary Study
by: Hind Dehbi, et al.
Published: (2013-01-01)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
by: D Sorcini, et al.
Published: (2023-11-01)

Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia
by: Yvyin Zhang, et al.
Published: (2023-01-01)

Flt3 Signaling in B Lymphocyte Development and Humoral Immunity
by: Kay L. Medina
Published: (2022-06-01)

Experience with FLT3 Inhibitor Midostaurin in Newly Diagnosed Acute Myeloid Leukemia Patients
by: Mehmet Baysal, et al.
Published: (2021-03-01)

FLT3 - ITD positive acute lymphocytic leukemia, does it impact on disease´s course?
by: Sebastian Kobold, et al.
Published: (2010-06-01)

Sex disparity in acute myeloid leukaemia with FLT3 internal tandem duplication mutations: implications for prognosis
by: Monica Hellesøy, et al.
Published: (2021-09-01)

Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure
by: Debora Capelli, et al.
Published: (2022-09-01)

Leukemic mutation FLT3-ITD is retained in dendritic cells and disrupts their homeostasis leading to expanded Th17 frequency
by: Patrick A. Flynn, et al.
Published: (2024-03-01)

Emergence of BCR–ABL1 Fusion in AML Post–FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance – A Case Series
by: Ahmad S. Alotaibi, et al.
Published: (2020-10-01)

The Clinical Utility of <i>FLT3</i> Mutation Testing in Acute Leukemia: A Canadian Consensus
by: Julie Bergeron, et al.
Published: (2023-12-01)

Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
by: Jonas S. Heitmann, et al.
Published: (2023-08-01)

Mutations within the Activation Loop Domain of FLT3 in Two Pediatric Patients with Refractory Infant Acute Myeloid Leukemia
by: Nicole Muhlbauer, et al.
Published: (2020-03-01)

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia
by: Peihong Wang, et al.
Published: (2021-07-01)

Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions
by: Kateryna Fedorov, et al.
Published: (2023-04-01)

FLT3 Mutation as a Significant Prognostic Marker in de novo Acute Myeloid Leukemia Patients: Incidence, Distribution and Association with Cytogenetic Findings in a Study from South India
by: Santhi Sarojam, et al.
Published: (2014-10-01)

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia
by: Melat T. Gebru, et al.
Published: (2020-11-01)

Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification
by: Raphael Brandão Moreira, et al.
Published: (2015-02-01)

Mutated Flt3Lg Provides Reduced Flt3 Recycling Compared to Wild-Type Flt3Lg and Retains the Specificity of Flt3Lg-Based CAR T-Cell Targeting in AML Models
by: Varvara Maiorova, et al.
Published: (2023-04-01)

Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression
by: Dengyang Zhang, et al.
Published: (2021-03-01)